Clin2
NCT06395519Worth exploringRecruiting

Study of ETX-19477 for advanced solid tumors

Advanced or Metastatic Solid TumorsBreast CancerOvarian CancerProstate CancerEpithelial Ovarian CancerBRCA2 MutationER+ Breast CancerCastrate Resistant Prostate Cancer

Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.

This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
120 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have an advanced solid tumor (except brain tumors) that has worsened after or is not tolerating your last treatment.
  • You have at least one tumor that can be measured on scans.
  • You are able to take care of yourself (ECOG score 0 or 1).
  • You have not taken any other experimental drug in the last 3 weeks (or 5 half-lives, whichever is shorter).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06799065Recruiting· Phase 1
Testing a new drug for advanced solid tumors

This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.

Aurora, Colorado
NCT07517198Recruiting· Phase 1
EXS74539 Study for Advanced Solid Tumors

This is an early-stage study testing a new cancer drug called EXS74539 to find the right dose and see how well it works in people with various advanced solid tumors. The drug may help patients whose cancers have stopped responding to standard treatments.

Los Angeles, California
NCT06249048Recruiting· Phase 1/Phase 2
Study of STX-001 injection for advanced solid tumors

This trial tests a new drug called STX-001, which is injected directly into a tumor to help the immune system fight cancer. It is being studied alone or with another immunotherapy (pembrolizumab) for people with advanced solid tumors, including melanoma or triple-negative breast cancer.

Scottsdale, Arizona
NCT06993844Recruiting· Phase 1/Phase 2
Study of ETX-636 for advanced solid tumors with PIK3CA mutation

This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.

Newport Beach, California
NCT07767474Not yet recruiting· Phase 1/Phase 2
Study of ATX-898 for advanced solid tumors

This trial tests a new drug, ATX-898, alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and effective.

NCT06533332Recruiting· Phase 1
Testing ERX-315 for advanced solid tumors

This trial tests a new drug called ERX-315 for people with advanced solid tumors (like breast, ovarian, pancreatic, endometrial, or liver cancer) that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.

Ryde, New South Wales

Hear when a new Advanced or Metastatic Solid Tumors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.